NIMH Pages About Alzheimer's Disease
Science News About Alzheimer's Disease
- Suppressing Protein May Stem Alzheimer’s Disease Process
Scientists funded by the National Institutes of Health have discovered a potential strategy for developing treatments to stem the disease process in Alzheimer’s disease, by blocking activity of a little-known regulator protein called CD33.
- Mental Decline Thwarted in Aging Rats
Scientists have discovered a compound that restores the capacity to form new memories in aging rats, likely by improving the survival of newborn neurons in the brain's memory hub. The research, funded in part by the National Institutes of Health, has turned up clues to a neuroprotective mechanism that could lead to a treatment for Alzheimer's disease.
- Use of Antipsychotics in Alzheimer’s Patients May Lead to Detrimental Metabolic Changes
Atypical antipsychotic medications are associated with weight gain and other metabolic changes among patients with Alzheimer’s disease, according to a recent analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) study. The study was published online ahead of print April 15, 2009, in the American Journal of Psychiatry.
- Antipsychotic Medications May Ease Some Alzheimer’s Symptoms, Not Others
Antipsychotic medications may lessen symptoms like hostility and aggression in patients with Alzheimer’s disease, but do not appear to lessen other symptoms or improve quality of life, according to a recent analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer’s Disease (CATIE-AD) study.
- Cortex Area Thinner in Youth with Alzheimer’s-Related Gene
A part of the brain first affected by Alzheimer’s disease is thinner in youth with a risk gene for the disorder, a brain imaging study by researchers at the National Institute of Mental Health (NIMH), one of the National Institutes of Health (NIH), has found.
Director’s Updates About Alzheimer's Disease
- NIMH Perspective on Treating Alzheimer’s Patients with Antipsychotic Medications
October 12, 2006
The recent publication of phase 1 results from the NIMH-funded Clinical Antipsychotic Trials in Intervention Effectiveness for Alzheimer's disease (CATIE-AD) in the New England Journal of Medicine provides new information about the use of several "atypical" antipsychotic medications for the treatment of psychotic symptoms in patients with Alzheimer's disease.